151 related articles for article (PubMed ID: 31784298)
1. A rare cause of acute coronary syndromes in young adults - myeloproliferative neoplasms: A case series.
Cengiz B; Aytekin V; Bildirici U; Sahin ST; Yurdakul S; Aytekin S; Kucukkaya R
Rev Port Cardiol (Engl Ed); 2019 Sep; 38(9):613-617. PubMed ID: 31784298
[TBL] [Abstract][Full Text] [Related]
2. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.
Stefanou MI; Richter H; Härtig F; Wang Y; Örgel A; Bender B; Mengel A; Ziemann U; Poli S
Eur J Neurol; 2019 Jun; 26(6):903-e64. PubMed ID: 30629793
[TBL] [Abstract][Full Text] [Related]
3. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
[TBL] [Abstract][Full Text] [Related]
5. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
[TBL] [Abstract][Full Text] [Related]
7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
10. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Büttner-Herold M; Sticht C; Wiech T; Porubsky S
Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Mattar MM; Nassef S; El Husseiny NM; El Masry MR; Salah M; Morad MA; Gawad AA
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e425-e429. PubMed ID: 31229378
[TBL] [Abstract][Full Text] [Related]
12. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
Todisco G; Manshouri T; Verstovsek S; Masarova L; Pierce SA; Keating MJ; Estrov Z
Leuk Lymphoma; 2016 May; 57(5):1054-9. PubMed ID: 26402369
[TBL] [Abstract][Full Text] [Related]
14. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
16. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
Takenaka K
Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
[TBL] [Abstract][Full Text] [Related]
17. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
18. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
[TBL] [Abstract][Full Text] [Related]
19. Essential Thrombocytosis in Patients <40 Years Old With Acute Coronary Syndromes: A Not So Uncommon Underlying Diagnosis Often Overlooked.
Kok L; Taverne LF; Verbeek EC; van de Wetering M; Voogel AJ; Oosterom L; Herrman JR; Kuipers RS
Cureus; 2022 Dec; 14(12):e32638. PubMed ID: 36654555
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]